New drug SAR441255 tested in humans for first time

NCT ID NCT04521738

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested a single dose of a new drug called SAR441255 in 48 healthy, lean to overweight adults. The main goal was to check safety and how the body processes the drug. Researchers also looked at effects on blood sugar and insulin levels. This is a first step to see if the drug might help with weight or diabetes in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAR441255

What this could lead to

If successful, this could point toward a new treatment for diabetes or weight management.

What could go wrong

This is a very early Phase 1 trial with only 48 participants, so it's mainly checking safety. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational site number 8400001

    Knoxville, Tennessee, 37920, United States